DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Toric Intraocular Lens Following Cataract Surgery

Not Applicable

Completed

Conditions: Cataract
Astigmatism

Interventions: Device: Toric Accommodating Lens
Device: Accommodating Lens

First Posted Date: 2010-06-09

Last Posted Date: 2014-09-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 229

Registration Number: NCT01140477

Locations: 🇺🇸
B&L Surgical, Bridgewater, New Jersey, United States

Feasibility of a New Silicone Hydrogel Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Investigational contact lens
Device: Acuvue Oasys Contact Lens
Device: Air Optix Aqua

First Posted Date: 2010-05-26

Last Posted Date: 2014-04-30

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 120

Registration Number: NCT01131130

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Marketed daily disposable contact lens
Device: Bausch & Lomb contact lens

First Posted Date: 2010-05-26

Last Posted Date: 2013-12-10

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 200

Registration Number: NCT01130974

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of 3 Intraocular Lenses Following Lens Extraction

Phase 4

Completed

Conditions: Cataract

Interventions: Device: ReSTOR
Device: Tecnis Multifocal IOL
Device: Crystalens AO

First Posted Date: 2010-05-13

Last Posted Date: 2014-03-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 78

Registration Number: NCT01122576

Locations: 🇺🇸
Bausch & Lomb, Inc, Aliso Viejo, California, United States

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Besifloxacin Ophthalmic Suspension 0.6%

First Posted Date: 2010-05-11

Last Posted Date: 2012-08-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 120

Registration Number: NCT01120418

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Redesigned Purevision Contact Lens
Device: PureVision Contact Lens

First Posted Date: 2010-05-06

Last Posted Date: 2020-10-06

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 376

Registration Number: NCT01118338

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Loteprednol etabonate suspension
Drug: Loteprednol etabonate base (QD)
Drug: Loteprednol etabonate base (BID)
Drug: Loteprednol etabonate base (QID)
Drug: Vehicle of loteprednol etabonate

First Posted Date: 2010-04-21

Last Posted Date: 2012-03-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 101

Registration Number: NCT01107405

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Inflammation
Pain

Interventions: Drug: Vehicle of Loteprednol Etabonate
Drug: Loteprednol etabonate

First Posted Date: 2010-02-02

Last Posted Date: 2012-01-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 407

Registration Number: NCT01060072

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Completed

Conditions: Inflammation
Uveitis

Interventions: Procedure: Fluocinolone Acetonide 0.59 mg
Procedure: Fluocinolone Acetonide 2.1 mg

First Posted Date: 2010-02-02

Last Posted Date: 2019-06-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 98

Registration Number: NCT01060787

Locations: 🇺🇸
Ophthalmic Partners of Boston, Boston, Massachusetts, United States

Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

Phase 3

Completed

Conditions: Conjunctivitis
Keratitis
Blepharitis

Interventions: Drug: Loteprednol and tobramycin
Drug: Tobramycin and dexamethasone

First Posted Date: 2009-12-09

Last Posted Date: 2012-02-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 357

Registration Number: NCT01028027

Locations: 🇸🇬
Bausch & Lomb Inc, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy